No single test can definitively diagnose dementia. Instead, doctors use a combination of cognitive screening, brain imaging, blood work, and sometimes spinal fluid analysis or specialized PET scans to build a complete picture. The process typically starts with short in-office screening tests and blood draws, then moves to more advanced tools if needed.
Cognitive Screening Tests
The first step is usually a brief cognitive screening in your doctor’s office. These are short, structured tasks that test memory, attention, language, and thinking speed. The most common ones take between 3 and 15 minutes.
The Mini-Cog is one of the quickest. You’re asked to remember three words, draw a clock face showing a specific time, then recall those three words. Its sensitivity for detecting dementia ranges from 76% to 100%, meaning it catches most cases, though it can also flag people who don’t actually have dementia.
The Montreal Cognitive Assessment (MoCA) is more detailed. It covers memory, attention, language, spatial reasoning, and abstract thinking, and takes about 10 minutes. Using a cutoff score of less than 26 out of 30, the MoCA picks up at least 94% of dementia cases. The trade-off is that its specificity is 60% or lower, so a low score doesn’t necessarily mean dementia is present.
The Mini-Mental State Examination (MMSE) was long considered the standard, but its accuracy varies widely. Sensitivity for all-cause dementia ranges from just 23% to 76%, meaning it can miss a significant number of cases. It performs somewhat better for Alzheimer’s specifically (sensitivity up to 89%) but poorly for vascular dementia, where one study found sensitivity of only 36%.
These screening tools are starting points, not final answers. A positive result signals the need for deeper evaluation, and a negative result doesn’t always rule dementia out.
Full Neuropsychological Testing
When screening results are borderline or when doctors need a more precise map of which mental abilities are affected, they refer you for formal neuropsychological testing. This is a much more thorough assessment, often taking several hours to complete.
A neuropsychologist will test general intellect, reading comprehension, language use, attention and concentration, processing speed, learning and memory, reasoning, and executive functions like planning, multitasking, and self-control. The pattern of strengths and weaknesses across these domains helps distinguish between types of dementia. Someone with early Alzheimer’s, for instance, typically shows pronounced memory deficits first, while someone with frontotemporal dementia may show personality changes and language problems with relatively preserved memory early on.
These results also establish a baseline. Repeating the testing a year or two later can reveal whether cognitive decline is progressing and how fast.
Blood Tests for Treatable Causes
Before pursuing a dementia diagnosis, doctors need to rule out conditions that mimic dementia but can be reversed with treatment. Several medical problems cause memory loss and confusion that look a lot like dementia but clear up once the underlying issue is addressed.
Standard blood work includes thyroid function tests and vitamin B12 levels, both recommended by the American Academy of Neurology as part of any initial dementia workup. A complete blood count, electrolyte panel, calcium, and glucose levels help screen for infections and metabolic problems that can impair thinking. Depending on your history, doctors may also check for liver or kidney dysfunction, syphilis, or HIV.
Hypothyroidism, B12 deficiency, and depression are among the most common reversible causes of cognitive decline. Catching them early matters because the cognitive symptoms often improve or resolve entirely with treatment.
Brain Imaging With MRI
An MRI of the brain is a core part of the dementia workup. It serves two purposes: ruling out structural problems like tumors, strokes, or fluid buildup, and identifying patterns of brain shrinkage that point toward specific types of dementia.
In Alzheimer’s disease, the pattern depends on age. People who develop Alzheimer’s after age 65 typically show focused shrinkage in the medial temporal lobes, particularly the hippocampi, the brain’s primary memory structures. Younger-onset Alzheimer’s tends to produce more widespread shrinkage across the parietal and temporal cortex, sometimes extending into the frontal lobes.
Frontotemporal dementia shows a distinctly different pattern, with volume loss concentrated in the frontal lobes and sometimes the front portions of the temporal lobes. Depending on the specific subtype, the shrinkage may be more prominent on one side of the brain. One form causes extensive left-sided anterior temporal lobe shrinkage, which helps explain why language problems are often an early symptom.
Normal-pressure hydrocephalus, a condition where excess fluid accumulates in the brain’s ventricles, is another finding that shows up clearly on MRI. This is one of the treatable causes of dementia-like symptoms, and it produces a characteristic shuffling, wide-based gait alongside cognitive decline.
The New Blood Test for Alzheimer’s
One of the biggest recent advances is a blood test that can detect the biological hallmarks of Alzheimer’s disease. In early 2025, the FDA cleared the first blood test designed to help diagnose Alzheimer’s. It measures the ratio of two proteins in a blood sample: a form of tau (p-tau 217) and a fragment of amyloid.
In a clinical study of 499 plasma samples from adults with cognitive impairment, 91.7% of people who tested positive on the blood test also had confirmed amyloid plaques on a PET scan or spinal fluid test. Among those who tested negative, 97.3% were confirmed negative by those same reference methods. That high negative predictive value is especially useful: a negative result gives strong reassurance that Alzheimer’s pathology is not present.
This test doesn’t replace imaging or clinical evaluation, but it can significantly streamline the diagnostic process. Previously, confirming amyloid buildup required either a PET scan costing thousands of dollars or a spinal tap, both of which are harder to access and more invasive than a blood draw.
Amyloid PET Scans and Spinal Fluid Analysis
When more definitive evidence is needed, two established methods can directly detect the abnormal proteins that define Alzheimer’s disease. Amyloid PET scans use a radioactive tracer that binds to amyloid plaques in the brain, making them visible on imaging. A positive scan confirms that plaques are present, though it doesn’t by itself prove they’re causing symptoms, since some older adults have amyloid deposits without cognitive decline.
Cerebrospinal fluid (CSF) analysis, obtained through a lumbar puncture, measures levels of amyloid and tau proteins directly. Low levels of one type of amyloid (amyloid-beta 42) combined with elevated tau suggest Alzheimer’s pathology. These fluid biomarkers and PET scans are now considered complementary rather than interchangeable. The 2024 diagnostic criteria from the National Institute on Aging and the Alzheimer’s Association acknowledge that fluid-based and imaging-based biomarkers don’t always agree perfectly, so doctors may use both when the clinical picture is unclear.
Those updated 2024 criteria also represent a fundamental shift in how Alzheimer’s is defined. The disease is now defined biologically, by the presence of abnormal biomarkers, rather than purely by clinical symptoms. This change matters because treatments that target amyloid plaques are now available, making accurate biological diagnosis more important than ever.
Genetic Testing
Genetic tests play a limited but specific role in the dementia workup. The most commonly discussed is the APOE gene test, which identifies which variant of the apolipoprotein E gene you carry. There are three versions: APOE2, APOE3, and APOE4. Carrying one or two copies of APOE4 increases your risk of developing Alzheimer’s, while APOE2 appears to be protective.
It’s important to understand that APOE testing is not diagnostic. No gene has been found to directly cause late-onset Alzheimer’s. Having APOE4 raises your risk, but many carriers never develop the disease, and many people with Alzheimer’s don’t carry it. When someone already has Alzheimer’s, however, knowing their APOE status can help guide treatment decisions.
For early-onset dementia (before age 65), genetic testing takes on a different significance. Mutations in genes like presenilin-1 are directly linked to familial Alzheimer’s and follow a dominant inheritance pattern, meaning a single copy virtually guarantees the disease will develop. Testing for these mutations is typically offered when there’s a strong family history of young-onset dementia.
The Physical and Neurological Exam
A standard physical and neurological exam is part of every dementia evaluation, even though findings are usually normal in people with common forms of dementia. The real value is in spotting clues that point to a treatable or atypical cause.
Doctors check reflexes, muscle tone, gait, eye movements, balance, and coordination. Prolonged reflexes can suggest hypothyroidism. A wide-based shuffling walk raises suspicion for normal-pressure hydrocephalus. Involuntary eye movements or difficulty with eye muscle control can point to Wernicke-Korsakoff syndrome, a condition caused by severe thiamine deficiency often related to chronic alcohol use. Abnormally brisk reflexes with slow limb movements may indicate HIV-related cognitive decline. Each of these findings redirects the diagnostic path toward a potentially reversible condition.